153 related articles for article (PubMed ID: 11070347)
1. Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen.
Mor G; Kohen F; Garcia-Velasco J; Nilsen J; Brown W; Song J; Naftolin F
J Steroid Biochem Mol Biol; 2000; 73(5):185-94. PubMed ID: 11070347
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Fas ligand expression by estrogen in normal ovary.
Sapi E; Brown WD; Aschkenazi S; Lim C; Munoz A; Kacinski BM; Rutherford T; Mor G
J Soc Gynecol Investig; 2002; 9(4):243-50. PubMed ID: 12113885
[TBL] [Abstract][Full Text] [Related]
3. Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.
Reimer T; Koczan D; Müller H; Friese K; Thiesen HJ; Gerber B
Breast Cancer Res; 2002; 4(5):R9. PubMed ID: 12223126
[TBL] [Abstract][Full Text] [Related]
4. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas.
Gutierrez LS; Eliza M; Niven-Fairchild T; Naftolin F; Mor G
Breast Cancer Res Treat; 1999 Apr; 54(3):245-53. PubMed ID: 10445423
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand.
Nagarkatti N; Davis BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):284-90. PubMed ID: 12721755
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol.
Song RX; Mor G; Naftolin F; McPherson RA; Song J; Zhang Z; Yue W; Wang J; Santen RJ
J Natl Cancer Inst; 2001 Nov; 93(22):1714-23. PubMed ID: 11717332
[TBL] [Abstract][Full Text] [Related]
9. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
10. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
13. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer.
O'Connell J; Bennett MW; O'Sullivan GC; Roche D; Kelly J; Collins JK; Shanahan F
J Pathol; 1998 Nov; 186(3):240-6. PubMed ID: 10211111
[TBL] [Abstract][Full Text] [Related]
15. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Fas ligand expression by estradiol and progesterone in human endometrium.
Selam B; Kayisli UA; Mulayim N; Arici A
Biol Reprod; 2001 Oct; 65(4):979-85. PubMed ID: 11566716
[TBL] [Abstract][Full Text] [Related]
17. Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors.
Herrnring C; Reimer T; Jeschke U; Makovitzky J; Krüger K; Gerber B; Kabelitz D; Friese K
Histochem Cell Biol; 2000 Mar; 113(3):189-94. PubMed ID: 10817673
[TBL] [Abstract][Full Text] [Related]
18. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
19. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
